<DOC>
	<DOCNO>NCT01537120</DOCNO>
	<brief_summary>This trial attempt develop use Continuous Glucose Monitoring ( CGM ) tool evaluation new exist pharmacological treatment type 2 diabetes , use twice daily administer dipeptidyl peptidase-4 ( DPP4 ) inhibitor , vildagliptin probe . The primary hypothesis two week treatment 50 mg oral Vildagliptin , twice daily lead statistically significant decrease 24 hour weighted-mean glucose ( WMG ) relative placebo .</brief_summary>
	<brief_title>Evaluation Continuous Glucose Monitoring Participants With Type 2 Diabetes Mellitus ( MK-0000-258 AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Clinical diagnosis type 2 diabetes mellitus clinical regimen metformin alone , maximum 3 gram per day , background lifestyle measure , Hemoglobin A1C screen &gt; 7 % . If antihyperglycemic therapy metformin sulfonylurea Screening Visit/Visit 1 Hemoglobin A1C &gt; = 6.5 % = &lt; 7.5 % , discontinue sulfonylurea usage undergo washout sulfonylurea . History either stroke , chronic seizure major neurological disorder within last 6 month . Untreated hypertension blood pressure &gt; 160/95 mmHg . History neoplastic disease within past 5 year . History hypersensitivity vildagliptin DPP4 inhibitor . Had major surgery , donate lose 1 unit ( 500 mL ) blood , participate another investigational study within 4 week prior screen . Used illicit drug abusively use alcohol within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>